

Katarzyna J Jerzak

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4308508/publications.pdf>

Version: 2024-02-01

48
papers

622
citations

840119

11
h-index

642321

23
g-index

49
all docs

49
docs citations

49
times ranked

817
citing authors

#	ARTICLE	IF	CITATIONS
1	ASCO, NCCN, MASCC/ESMO: a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in adult patients. <i>Supportive Care in Cancer</i> , 2019, 27, 87-95.	1.0	103
2	The incidence of brain metastases among patients with metastatic breast cancer: a systematic review and meta-analysis. <i>Neuro-Oncology</i> , 2021, 23, 894-904.	0.6	95
3	Personalized Breast Cancer Treatments Using Artificial Intelligence in Radiomics and Pathomics. <i>Journal of Medical Imaging and Radiation Sciences</i> , 2019, 50, S32-S41.	0.2	48
4	Endocrine therapy in endometrial cancer: An old dog with new tricks. <i>Gynecologic Oncology</i> , 2019, 153, 175-183.	0.6	48
5	Incidence of Brain Metastases in Nonmetastatic and Metastatic Breast Cancer: Is There a Role for Screening?. <i>Clinical Breast Cancer</i> , 2020, 20, e54-e64.	1.1	41
6	Thyroid hormone receptor β in breast cancer: prognostic and therapeutic implications. <i>Breast Cancer Research and Treatment</i> , 2015, 149, 293-301.	1.1	35
7	Central nervous system-specific efficacy of CDK4/6 inhibitors in randomized controlled trials for metastatic breast cancer. <i>Oncotarget</i> , 2019, 10, 6317-6322.	0.8	30
8	Machine Learning Frameworks to Predict Neoadjuvant Chemotherapy Response in Breast Cancer Using Clinical and Pathological Features. <i>JCO Clinical Cancer Informatics</i> , 2021, 5, 66-80.	1.0	25
9	Patients'™ and Oncologists'™ Knowledge and Expectations Regarding Tumor Multigene Next-Generation Sequencing: A Narrative Review. <i>Oncologist</i> , 2021, 26, e1359-e1371.	1.9	16
10	Incidence and real-world burden of brain metastases from solid tumors and hematologic malignancies in Ontario: a population-based study. <i>Neuro-Oncology Advances</i> , 2021, 3, vdaa178.	0.4	16
11	Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical Considerations. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz050.	1.4	15
12	Central Nervous System-Specific Outcomes of Phase 3 Randomized Clinical Trials in Patients With Advanced Breast Cancer, Lung Cancer, and Melanoma. <i>JAMA Oncology</i> , 2021, 7, 1062.	3.4	13
13	A population-based comparison of treatment patterns, resource utilization, and costs by cancer stage for Ontario patients with triple-negative breast cancer. <i>Cancer Medicine</i> , 2020, 9, 7548-7557.	1.3	12
14	Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 2: Approaches to Predict and Identify Late Recurrence, Research Directions. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz049.	1.4	11
15	Trastuzumab emtansine increases the risk of stereotactic radiosurgery-induced radionecrosis in HER2-positive breast cancer. <i>Journal of Neuro-Oncology</i> , 2022, 159, 177-183.	1.4	10
16	Prevention of carboplatin-induced hypersensitivity reactions in women with ovarian cancer. <i>Journal of Oncology Pharmacy Practice</i> , 2018, 24, 83-90.	0.5	9
17	Treatment Patterns and Outcomes of Women with Symptomatic and Asymptomatic Breast Cancer Brain Metastases: A Single-Center Retrospective Study. <i>Oncologist</i> , 2021, 26, e1951-e1961.	1.9	9
18	Takotsubo Cardiomyopathy During Anti-HER2 Therapy for Metastatic Breast Cancer. <i>Oncologist</i> , 2019, 24, e80-e82.	1.9	8

#	ARTICLE	IF	CITATIONS
19	Breast cancer diagnosed in the post-weaning period is indicative for a poor outcome. <i>European Journal of Cancer</i> , 2021, 155, 13-24.	1.3	7
20	Assessment of Digital Pathology Imaging Biomarkers Associated with Breast Cancer Histologic Grade. <i>Current Oncology</i> , 2021, 28, 4298-4316.	0.9	7
21	A population-based comparison of treatment patterns, resource utilization, and costs by cancer stage for Ontario patients with hormone receptor-positive/HER2-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 185, 507-515.	1.1	6
22	HER2-targeted therapy prolongs survival in patients with HER2-positive breast cancer and intracranial metastatic disease: a systematic review and meta-analysis. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa136.	0.4	6
23	Role of bone-modifying agents in advanced cancer. <i>Annals of Palliative Medicine</i> , 2020, 9, 1314-1323.	0.5	5
24	Prognostic associations of plasma hepcidin in women with early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 184, 927-935.	1.1	5
25	Clinical outcomes and prognostic biomarkers among pregnant, post-partum and nulliparous women with breast cancer: a prospective cohort study. <i>Breast Cancer Research and Treatment</i> , 2021, 189, 797-806.	1.1	5
26	Assessing the Association of Targeted Therapy and Intracranial Metastatic Disease. <i>JAMA Oncology</i> , 2021, 7, 1220.	3.4	5
27	Cetuximab plus irinotecan versus panitumumab in patients with refractory metastatic colorectal cancer in Ontario, Canada. <i>International Journal of Cancer</i> , 2017, 140, 2162-2167.	2.3	4
28	Targeted metabolomics in colorectal cancer: a strategic approach using standardized laboratory tests of the blood and urine. <i>Hypoxia (Auckland, N Z)</i> , 2017, Volume 5, 61-66.	1.9	4
29	Intracranial Metastatic Disease: Present Challenges, Future Opportunities. <i>Frontiers in Oncology</i> , 2022, 12, 855182.	1.3	4
30	An update on adjuvant systemic therapy for elderly patients with early breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1881-1888.	0.9	3
31	Salivary gland-type mammary carcinoma arising in microglandular adenosis: A case report and clinicopathological review of the literature. <i>Cancer Treatment and Research Communications</i> , 2020, 24, 100178.	0.7	3
32	RE: Long-term Safety of Pregnancy Following Breast Cancer According to Estrogen Receptor Status. <i>Journal of the National Cancer Institute</i> , 2018, 110, 918-918.	3.0	2
33	Evaluation of the impact of patient involvement in health technology assessments: A scoping review. <i>International Journal of Technology Assessment in Health Care</i> , 2020, 36, 217-223.	0.2	2
34	A population-based comparison of treatment, resource utilization, and costs by cancer stage for Ontario patients with HER2-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 185, 807-815.	1.1	2
35	Dual- versus single-agent HER2 inhibition and incidence of intracranial metastatic disease: a systematic review and meta-analysis. <i>Npj Breast Cancer</i> , 2021, 7, 17.	2.3	2
36	Data describing the poor outcome associated with a breast cancer diagnosis in the post-weaning period. <i>Data in Brief</i> , 2021, 38, 107354.	0.5	2

#	ARTICLE	IF	CITATIONS
37	Ovarian Sex Cord-Stromal Tumors: The Challenge of Rare Gynecologic Malignancies. Journal of Oncology Practice, 2016, 12, 947-948.	2.5	1
38	An update on treatment for post-menopausal metastatic breast cancer in elderly patients. Expert Opinion on Pharmacotherapy, 2018, 19, 597-609.	0.9	1
39	A growing vulvar mass in a post-menopausal woman. Lancet Oncology, The, 2021, 22, e530.	5.1	1
40	Exclusion of Patients With Brain Metastases in Published Phase III Clinical Trials for Advanced Breast Cancer. Clinical Breast Cancer, 2022, 22, 629-633.	1.1	1
41	P2€34: Cognitive Sequelae of Adjuvant Endocrine therapy for the Treatment of Breast Cancer in Older Women: A Feasibility Study. Alzheimer's and Dementia, 2016, 12, P770.	0.4	0
42	61. EXPRESSION OF ANDROGEN RECEPTOR IN BREAST CANCER BRAIN METASTASIS. Neuro-Oncology Advances, 2020, 2, ii13-ii13.	0.4	0
43	Abstract PS10-33: Analysis of factors associated with pathological complete response (pCR) in patients with HER2+ breast cancer receiving neoadjuvant chemotherapy. , 2021, , .		0
44	Abstract PS11-20: Radiation therapy (RT) induced toxicity in advanced breast cancer (ABC) patients treated with CDK4/6 inhibitors (CDK4/6is). , 2021, , .		0
45	Reply to letter by Schwartz et al.. Neuro-Oncology, 2021, 23, 1406-1407.	0.6	0
46	THER-01. Targeted therapy and intracranial metastatic disease: a population-based retrospective cohort study. Neuro-Oncology Advances, 2021, 3, iii12-iii12.	0.4	0
47	BIOM-07. EXPRESSION OF ANDROGEN RECEPTOR AND PROGRAMMED DEATH-LIGAND 1 IN BREAST-TO-BRAIN-METASTASES.. Neuro-Oncology, 2020, 22, ii2-ii3.	0.6	0
48	Abstract P5-13-17: PD-L1 expression in breast to brain metastases. Cancer Research, 2022, 82, P5-13-17-P5-13-17.	0.4	0